Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metformin for Immune Homeostasis in Injection Drug Users (MET-IH)
NCT06829238Phase 4Recruiting
- Sponsor
- University of Alabama at Birmingham
- Start
- Apr 2025
- Primary completion
- Nov 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in systemic inflammation and immune dysregulation comparing Metformin Group with Placebo Group (2 arms). Primary endpoint: Change in Serum C-reactive Protein at 16 weeks. Started Apr 2025; status: recruiting.
02
Drugs
metformin
03
Conditions
systemic inflammationimmune dysregulation
Beyond the preview
Go deeper on NCT06829238.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06829238.